6533b821fe1ef96bd127b734
RESEARCH PRODUCT
Soft Tissue Sarcomas (STS)
Massimiliano CaniBruno VincenziLorena IncorvaiaGiuseppe Badalamentisubject
ChemotherapyHeterogeneous groupAnthracyclinebusiness.industrymedicine.medical_treatmentMesenchymal stem cellmedicineCancer researchSoft tissueSingle agentProgenitor cellbusinessdescription
Soft tissue sarcomas (STSs) represent a rare and heterogeneous group of solid tumors derived from mesenchymal progenitors and account for 1% of all adult malignancies. Although in the last decade anthracycline-based chemotherapy single agent or in combination has been able to improve clinical benefits, prognosis is still poor, and STSs represent an important unmet medical need.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2021-01-01 |